APLS
Apellis Pharmaceuticals, Inc.
Price Chart
Latest Quote
$41.03
+0.00 (+0.00%)
Current Price
| Previous Close | $41.03 |
| Open | $41.05 |
| Day High | $41.03 |
| Day Low | $41.03 |
| Volume | 28,642,670 |
Stock Information
| Shares Outstanding | 128.02M |
| Total Debt | $475.76M |
| Cash Equivalents | $406.20M |
| Revenue | $1.11B |
| Net Income | $133.27M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.25B |
| P/E Ratio | 38.35 |
| EPS (TTM) | $1.07 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.32B |
| Sales | $1.11B |
| Income | $133.27M |
| Book/sh | $3.24 |
| Cash/sh | $3.17 |
| Employees | 733 |
Financial Ratios
| Quick Ratio | 3.00 |
| Current Ratio | 3.63 |
| Debt/Eq | 114.66 |
Returns & Margins
| ROA | 10.93% |
| ROE | 46.02% |
| Gross Margin | 64.28% |
| Operating Margin | 9.87% |
| Profit Margin | 12.06% |
Ownership
| Insider Ownership | 11.36% |
| Institutional Ownership | 110.43% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -130.55 |
| P/S | 4.75 |
| P/B | 12.65 |
Analyst Data
| Recommendation | hold |
| Target Price | $40.92 |
Technical Indicators
| SMA20 | $40.99 |
| SMA50 | $33.20 |
| SMA200 | $26.08 |
| RSI | 58.70 |
| ATR | 0.0568 |
| Shares Float | 83.22M |
| Short Float | 12.55% |
| Short Ratio | 1.15 |
| Volatility | -0.25 |
Performance History
| Week | +0.00% |
| Month | +0.39% |
| Quarter | +89.08% |
| 6 Months | +104.95% |
| YTD | +58.66% |
| Year | +145.69% |
| 3 Years | -55.10% |
| 5 Years | -9.13% |
| 10 Years | +192.44% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-05-15 | $41.03 | 0 |
| 2026-05-14 | $41.03 | 0 |
| 2026-05-13 | $41.03 | 68,611,411 |
| 2026-05-12 | $41.06 | 7,931,662 |
| 2026-05-11 | $41.02 | 9,021,713 |
| 2026-05-08 | $41.03 | 7,067,495 |
| 2026-05-07 | $41.01 | 8,392,648 |
| 2026-05-06 | $41.12 | 3,719,972 |
| 2026-05-05 | $40.97 | 2,838,568 |
| 2026-05-04 | $40.97 | 2,517,827 |
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. As of May 14, 2026, Apellis Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.
đ° Latest News
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
MarketBeat âĸ 2026-05-22T11:50:00Z
Biogenâs Apellis Deal And Alzheimerâs Trial Shift Focus Beyond Price
Simply Wall St. âĸ 2026-05-18T19:17:46Z
Biogen completes $5.3B Apellis Pharmaceuticals acquisition
Quartz âĸ 2026-05-15T11:44:37Z
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics
Zacks âĸ 2026-05-07T20:00:01Z
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-07T19:25:01Z
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Should You Buy?
Zacks âĸ 2026-05-01T14:00:07Z
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?
Zacks âĸ 2026-04-29T14:00:27Z
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
Zacks âĸ 2026-04-24T13:04:00Z
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy
Zacks âĸ 2026-04-22T16:32:00Z
Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy Alliance
Simply Wall St. âĸ 2026-04-19T20:04:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $102,236,000 | $117,723,000 | $58,510,000 | $5,636,000 |
| Cost Of Revenue | $102,236,000 | $117,723,000 | $58,510,000 | $5,636,000 |
| Total Revenue | $1,003,782,000 | $781,367,000 | $396,591,000 | $75,422,000 |
| Operating Revenue | $1,003,782,000 | $781,367,000 | $396,591,000 | $75,422,000 |
| Expenses | ||||
| Interest Expense | $44,327,000 | $40,391,000 | $29,581,000 | $32,626,000 |
| Total Expenses | $948,355,000 | $946,346,000 | $913,712,000 | $670,035,000 |
| Other Income Expense | $-133,000 | $-4,119,000 | $-727,000 | $-33,178,000 |
| Other Non Operating Income Expenses | $-133,000 | $-2,170,000 | $-727,000 | $-288,000 |
| Net Non Operating Interest Income Expense | $-31,184,000 | $-27,618,000 | $-8,648,000 | $-23,712,000 |
| Interest Expense Non Operating | $44,327,000 | $40,391,000 | $29,581,000 | $32,626,000 |
| Operating Expense | $846,119,000 | $828,623,000 | $855,202,000 | $664,399,000 |
| General And Administrative Expense | - | - | $500,815,000 | $277,163,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $22,388,000 | $-197,878,000 | $-528,628,000 | $-652,172,000 |
| Net Interest Income | $-31,184,000 | $-27,618,000 | $-8,648,000 | $-23,712,000 |
| Interest Income | $13,143,000 | $12,773,000 | $20,933,000 | $8,914,000 |
| Normalized Income | $22,388,000 | $-196,338,290 | $-528,628,000 | $-626,188,900 |
| Net Income From Continuing And Discontinued Operation | $22,388,000 | $-197,878,000 | $-528,628,000 | $-652,172,000 |
| Total Operating Income As Reported | $55,427,000 | $-164,979,000 | $-517,121,000 | $-594,613,000 |
| Net Income Common Stockholders | $22,388,000 | $-197,878,000 | $-528,628,000 | $-652,172,000 |
| Net Income | $22,388,000 | $-197,878,000 | $-528,628,000 | $-652,172,000 |
| Net Income Including Noncontrolling Interests | $22,388,000 | $-197,878,000 | $-528,628,000 | $-652,172,000 |
| Net Income Continuous Operations | $22,388,000 | $-197,878,000 | $-528,628,000 | $-652,172,000 |
| Pretax Income | $24,110,000 | $-196,716,000 | $-526,496,000 | $-651,503,000 |
| Special Income Charges | $0 | $-1,949,000 | $0 | $-32,890,000 |
| Interest Income Non Operating | $13,143,000 | $12,773,000 | $20,933,000 | $8,914,000 |
| Operating Income | $55,427,000 | $-164,979,000 | $-517,121,000 | $-594,613,000 |
| Gross Profit | $901,546,000 | $663,644,000 | $338,081,000 | $69,786,000 |
| Per Share | ||||
| Diluted EPS | $0.18 | $-1.60 | $-4.45 | $-6.15 |
| Basic EPS | $0.18 | $-1.60 | $-4.45 | $-6.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-409,290 | $0 | $-6,906,900 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $69,995,000 | $-152,579,000 | $-495,131,000 | $-584,435,000 |
| Total Unusual Items | $0 | $-1,949,000 | $0 | $-32,890,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-1,949,000 | $0 | $-32,890,000 |
| Reconciled Depreciation | $1,558,000 | $1,797,000 | $1,784,000 | $1,552,000 |
| EBITDA (Bullshit earnings) | $69,995,000 | $-154,528,000 | $-495,131,000 | $-617,325,000 |
| EBIT | $68,437,000 | $-156,325,000 | $-496,915,000 | $-618,877,000 |
| Diluted Average Shares | $129,855,000 | $123,905,000 | $118,678,000 | $106,114,000 |
| Basic Average Shares | $126,145,000 | $123,905,000 | $118,678,000 | $106,114,000 |
| Diluted NI Availto Com Stockholders | $22,388,000 | $-197,878,000 | $-528,628,000 | $-652,172,000 |
| Tax Provision | $1,722,000 | $1,162,000 | $2,132,000 | $669,000 |
| Research And Development | $295,854,000 | $327,570,000 | $354,387,000 | $387,236,000 |
| Selling General And Administration | $550,265,000 | $501,053,000 | $500,815,000 | $277,163,000 |
| Other Special Charges | - | $1,949,000 | - | $32,890,000 |
| Other Gand A | - | - | $500,815,000 | $277,163,000 |
| Gain On Sale Of Security | - | - | - | - |
Fetched: 2026-04-27
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $370,147,000 | $228,539,000 | $194,521,000 | $169,872,000 |
| Total Assets | $1,075,257,000 | $885,051,000 | $788,730,000 | $760,217,000 |
| Total Non Current Assets | $60,417,000 | $96,097,000 | $22,399,000 | $40,694,000 |
| Other Non Current Assets | $40,514,000 | $77,062,000 | $1,309,000 | $15,799,000 |
| Current Assets | $1,014,840,000 | $788,954,000 | $766,331,000 | $719,523,000 |
| Other Current Assets | $1,553,000 | $4,847,000 | $4,354,000 | $6,505,000 |
| Restricted Cash | $1,527,000 | $1,322,000 | $1,114,000 | $1,273,000 |
| Prepaid Assets | $33,812,000 | $18,368,000 | $38,820,000 | $36,350,000 |
| Inventory | $142,556,000 | $81,404,000 | $146,362,000 | $85,714,000 |
| Receivables | $369,159,000 | $271,723,000 | $224,496,000 | $37,880,000 |
| Other Receivables | $2,938,000 | $6,797,000 | $18,054,000 | $21,442,000 |
| Accounts Receivable | $366,221,000 | $264,926,000 | $206,442,000 | $7,727,000 |
| Cash Cash Equivalents And Short Term Investments | $466,233,000 | $411,290,000 | $351,185,000 | $551,801,000 |
| Cash And Cash Equivalents | $466,233,000 | $411,290,000 | $351,185,000 | $551,801,000 |
| Taxes Receivable | - | - | $0 | $8,711,000 |
| Debt | ||||
| Total Debt | $474,360,000 | $469,784,000 | $110,928,000 | $112,713,000 |
| Long Term Debt And Capital Lease Obligation | $373,611,000 | $463,031,000 | $104,487,000 | $107,088,000 |
| Long Term Debt | $361,664,000 | $452,830,000 | $93,033,000 | $92,736,000 |
| Current Debt And Capital Lease Obligation | $100,749,000 | $6,753,000 | $6,441,000 | $5,625,000 |
| Current Debt | $93,662,000 | - | - | - |
| Other Current Borrowings | $93,662,000 | - | - | - |
| Net Debt | - | $41,540,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $705,110,000 | $656,512,000 | $594,209,000 | $590,345,000 |
| Total Non Current Liabilities Net Minority Interest | $381,514,000 | $471,003,000 | $346,616,000 | $422,735,000 |
| Other Non Current Liabilities | $7,903,000 | $7,972,000 | $242,129,000 | $315,647,000 |
| Current Liabilities | $323,596,000 | $185,509,000 | $247,593,000 | $167,610,000 |
| Payables And Accrued Expenses | $169,600,000 | $133,611,000 | $165,322,000 | $132,481,000 |
| Payables | $56,798,000 | $38,572,000 | $37,516,000 | $37,342,000 |
| Accounts Payable | $56,798,000 | $38,572,000 | $37,516,000 | $37,342,000 |
| Other Current Liabilities | - | - | $75,830,000 | $29,504,000 |
| Derivative Product Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $370,147,000 | $228,539,000 | $194,521,000 | $169,872,000 |
| Total Equity Gross Minority Interest | $370,147,000 | $228,539,000 | $194,521,000 | $169,872,000 |
| Stockholders Equity | $370,147,000 | $228,539,000 | $194,521,000 | $169,872,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,103,000 | $-3,308,000 | $-3,542,000 | $-875,000 |
| Other Equity Adjustments | $-2,103,000 | $-3,308,000 | $-3,542,000 | $-875,000 |
| Retained Earnings | $-3,012,978,000 | $-3,035,366,000 | $-2,837,488,000 | $-2,308,860,000 |
| Other | ||||
| Ordinary Shares Number | $126,621,000 | $124,495,000 | $119,556,000 | $110,771,975 |
| Share Issued | $126,621,000 | $124,495,000 | $119,556,000 | $110,771,975 |
| Tangible Book Value | $370,147,000 | $228,539,000 | $194,521,000 | $169,872,000 |
| Invested Capital | $825,473,000 | $681,369,000 | $287,554,000 | $262,608,000 |
| Working Capital | $691,244,000 | $603,445,000 | $518,738,000 | $551,913,000 |
| Capital Lease Obligations | $19,034,000 | $16,954,000 | $17,895,000 | $19,977,000 |
| Total Capitalization | $731,811,000 | $681,369,000 | $287,554,000 | $262,608,000 |
| Additional Paid In Capital | $3,385,216,000 | $3,267,201,000 | $3,035,539,000 | $2,479,596,000 |
| Capital Stock | $12,000 | $12,000 | $12,000 | $11,000 |
| Common Stock | $12,000 | $12,000 | $12,000 | $11,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $11,947,000 | $10,201,000 | $11,454,000 | $14,352,000 |
| Current Capital Lease Obligation | $7,087,000 | $6,753,000 | $6,441,000 | $5,625,000 |
| Current Provisions | $53,247,000 | $45,145,000 | - | - |
| Current Accrued Expenses | $112,802,000 | $95,039,000 | $127,806,000 | $95,139,000 |
| Net PPE | $19,903,000 | $19,035,000 | $21,090,000 | $24,895,000 |
| Gross PPE | $19,903,000 | $19,035,000 | $21,090,000 | $24,895,000 |
| Other Properties | $19,903,000 | $19,035,000 | $21,090,000 | $24,895,000 |
| Treasury Shares Number | - | - | $0 | - |
| Finished Goods | - | - | $30,714,000 | $1,766,000 |
| Work In Process | - | - | $82,924,000 | $54,101,000 |
| Raw Materials | - | - | $32,724,000 | $29,847,000 |
| Other Short Term Investments | - | - | - | $0 |
Fetched: 2026-04-27
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $45,014,000 | $-88,269,000 | $-595,508,000 | $-515,269,000 |
| Operating Activities | ||||
| Operating Cash Flow | $45,327,000 | $-87,866,000 | $-594,735,000 | $-513,745,000 |
| Cash Flow From Continuing Operating Activities | $45,327,000 | $-87,866,000 | $-594,735,000 | $-513,745,000 |
| Operating Gains Losses | - | $1,949,000 | $120,000 | $32,890,000 |
| Investing Activities | ||||
| Capital Expenditure | $-313,000 | $-403,000 | $-773,000 | $-1,524,000 |
| Investing Cash Flow | $-313,000 | $-403,000 | $-674,000 | $59,893,000 |
| Cash Flow From Continuing Investing Activities | $-313,000 | $-403,000 | $-674,000 | $59,893,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $384,387,000 | $380,120,000 |
| Financing Cash Flow | $8,884,000 | $149,241,000 | $394,499,000 | $365,659,000 |
| Cash Flow From Continuing Financing Activities | $8,884,000 | $149,241,000 | $394,499,000 | $365,659,000 |
| Net Other Financing Charges | $-11,000 | $-235,041,000 | $-66,540,000 | $-40,182,000 |
| Net Common Stock Issuance | $0 | $0 | $384,387,000 | $380,120,000 |
| Common Stock Issuance | $0 | $0 | $384,387,000 | $380,120,000 |
| Other | ||||
| Issuance Of Debt | $0 | $365,454,000 | $0 | $0 |
| Interest Paid Supplemental Data | $41,233,000 | $29,368,000 | $3,286,000 | $5,003,000 |
| End Cash Position | $467,760,000 | $412,612,000 | $352,299,000 | $553,074,000 |
| Beginning Cash Position | $412,612,000 | $352,299,000 | $553,074,000 | $641,755,000 |
| Effect Of Exchange Rate Changes | $1,250,000 | $-659,000 | $135,000 | $-488,000 |
| Changes In Cash | $53,898,000 | $60,972,000 | $-200,910,000 | $-88,193,000 |
| Proceeds From Stock Option Exercised | $8,895,000 | $18,828,000 | $76,652,000 | $25,721,000 |
| Net Issuance Payments Of Debt | $0 | $365,454,000 | $0 | $0 |
| Net Long Term Debt Issuance | $0 | $365,454,000 | $0 | $0 |
| Long Term Debt Issuance | $0 | $365,454,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-313,000 | $-403,000 | $-674,000 | $-1,524,000 |
| Sale Of PPE | $0 | $0 | $99,000 | $0 |
| Purchase Of PPE | $-313,000 | $-403,000 | $-773,000 | $-1,524,000 |
| Change In Working Capital | $-85,118,000 | $-18,357,000 | $-200,249,000 | $-15,763,000 |
| Change In Other Working Capital | $-34,000 | $-277,000 | $-80,000 | $-65,000 |
| Change In Other Current Assets | $-4,061,000 | $705,000 | $11,700,000 | $50,426,000 |
| Change In Payables And Accrued Expense | $43,610,000 | $19,241,000 | $35,120,000 | $12,377,000 |
| Change In Accrued Expense | $25,387,000 | $18,152,000 | $34,950,000 | $-6,312,000 |
| Change In Payable | $18,223,000 | $1,089,000 | $170,000 | $18,689,000 |
| Change In Account Payable | $18,223,000 | $1,089,000 | $170,000 | $18,689,000 |
| Change In Prepaid Assets | $-8,087,000 | $31,213,000 | $12,373,000 | $-11,479,000 |
| Change In Inventory | $-15,267,000 | $-10,755,000 | $-60,647,000 | $-69,397,000 |
| Change In Receivables | $-101,279,000 | $-58,484,000 | $-198,715,000 | $2,375,000 |
| Changes In Account Receivables | $-101,279,000 | $-58,484,000 | $-198,715,000 | $2,375,000 |
| Other Non Cash Items | $2,496,000 | $10,495,000 | $26,293,000 | $28,663,000 |
| Stock Based Compensation | $104,003,000 | $114,128,000 | $105,945,000 | $91,085,000 |
| Depreciation Amortization Depletion | $1,558,000 | $1,797,000 | $1,784,000 | $1,552,000 |
| Depreciation And Amortization | $1,558,000 | $1,797,000 | $1,784,000 | $1,552,000 |
| Depreciation | $1,558,000 | $1,797,000 | $1,784,000 | $1,552,000 |
| Gain Loss On Sale Of PPE | $0 | $0 | $120,000 | $0 |
| Net Income From Continuing Operations | $22,388,000 | $-197,878,000 | $-528,628,000 | $-652,172,000 |
| Income Tax Paid Supplemental Data | - | $1,649,000 | $0 | $4,915,000 |
| Net Investment Purchase And Sale | - | $0 | $0 | $61,417,000 |
| Sale Of Investment | - | $0 | $0 | $393,280,000 |
| Purchase Of Investment | - | $0 | $0 | $-331,863,000 |
| Repayment Of Debt | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Change In Other Current Liabilities | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-04-27